ETFs positioned on Lundbeck

Name YTD change Weight AuM
+11.91%-.--% 67 M€
+6.43%-.--% 49 M€
+12.90%-.--% 27,154 M€
+1.83%-.--% 51 M€
+10.87%0% 30,947 M€
+2.63%0% 453 M€
+13.21%0% 3,469 M€
+10.39%0% 121 M€
+11.00%0% 5,614 M€
+18.16%0% 8,192 M€
+12.24%0% 361 M€
+11.67%0% 151 M€
+9.52%0% 41 M€
+14.45%0% 9,865 M€
+13.17%0% 32,566 M€
+11.57%0% 497 M€
+17.39%0% 961 M€
+17.58%0% 237,840 M€
+8.56%0% 33,076 M€
+15.42%0% 1,674 M€
+12.55%0% 69 M€
+14.63%0% 6,852 M€
+16.59%0% 70,454 M€
+16.41%0% 163,510 M€
+11.95%0% 4,850 M€
+1.48%0% 1,110 M€
+14.63%0% 18,816 M€
+11.07%0% 81 M€
+12.77%0% 31 M€
+13.57%0% 331 M€
+14.92%0% 2,612 M€
+16.59%0% 1,199 M€
+16.31%0% 12,086 M€
+14.99%0% 39 M€
+14.04%0% 81,610 M€
+12.19%0% 576 M€
+12.07%0% 7,793 M€
+8.63%0% 4,204 M€
+11.29%0% 526 M€
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
41.80DKK
Average target price
48.73DKK
Spread / Average Target
+16.58%

Quarterly revenue - Rate of surprise